We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Gelnique (oxybutynin chloride)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Gelnique (oxybutynin chloride)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Gelnique (oxybutynin chloride) is an antispasmodic, antimuscarinic agent. It acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. In conditions characterized by involuntary detrusor contractions, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction.

    Gelnique is specifically indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

    Gelnique is supplied as a gel designed for topical administration. The recommended initial dose of the drug is one sachet (a 1 gram unit dose (1.14 mL) of 100 mg/g) applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs. Application sites should be rotated.

    Clinical Results

    FDA Approval
    FDA approval of Gelnique was based on the results a single randomized, double-blind, placebo-controlled, parallel group 12-week study. The study entolled 789 subjects with symptomatic overactive bladder with an average of at least four incontinence episodes in a 3-day period and at least 8 micturitions per day. The subjects were randomized to daily applications of Gelnique 1 gram or matching placebo gel. Gelnique treatment resulted in a statistically significant decrease in the number of urinary incontinence episodes per day from baseline to endpoint (the primary efficacy endpoint) compared with placebo (p<0.0001) as well as a decrease in the average daily urinary frequency (p=0.0017) and an increase in the average urine volume per void (p=0.0018).

    Side Effects

    Adverse events associated with the use of Gelnique may include, but are not limited to, the following:

    • dry mouth
    • urinary tract infection
    • application site reactions
    • upper respiratory tract infections
    • dizziness
    • nasopharyngitis

    Mechanism of Action

    Gelnique (oxybutynin chloride) is an antispasmodic, antimuscarinic agent. It acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. In conditions characterized by involuntary detrusor contractions, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction.

    Literature References

    Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. Journal of the American Geriatrics Society 2008 May;56(5):862-70

    Sahai A, Mallina R, Dowson C, Larner T, Khan MS Evolution of transdermal oxybutynin in the treatment of overactive bladder. International Journal of Clinical Practice 2008 Jan;62(1):167-70

    Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. International Journal of Clinical Practice 2008 Jan;62(1):27-38

    Reiz JL, Salem P, Darke AC Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. Journal of Clinical Pharmacology 2007 Mar;47(3):351-7

    Sand P, Zinner N, Newman D, Lucente V, Dmochowski R, Kelleher C, Dahl NV Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU International 2007 Apr;99(4):836-44

    Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World Journal of Urology 2005 Sep;23(4):263-70

    Additional Information

    For additional information regarding Gelnique or overactive bladder, please visit the Gelnique web page.
    Approval Date: 2009-01-01
    Date Created: 2009-02-13 12:00:00
    Company Name: Watson Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    • China-360x240

      U.S. Tops List of Trial Startups With China Making Progress in Phase 1

    • Phoneapp-360x240

      Device Apps Present Unique Risks in Trials

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing